Progress of vaccine and drug development for Ebola preparedness.
- Author:
Woo Young CHOI
1
;
Kee Jong HONG
;
Joo Eun HONG
;
Won Ja LEE
Author Information
- Publication Type:Review
- Keywords: Ebola virus; Vaccines; Drug development; Ebola hemorrhagic fever
- MeSH: Africa, Western; Ebolavirus; Guinea; Hemorrhagic Fever, Ebola; Humans; Models, Animal; Vaccines; World Health Organization
- From:Clinical and Experimental Vaccine Research 2015;4(1):11-16
- CountryRepublic of Korea
- Language:English
- Abstract: Since the first case of Ebola virus disease (EVD) in Guinea was reported in March 2014 by World Health Organization (WHO), the outbreak has continued through the year and the total number of 19,065 patients was reported as the confirmed or suspected in the EVD-affected countries. Among the cases, 7,388 patients were reported death by 19 December. Currently, available therapeutics to treat the infected patients or vaccines to prevent people from infection is not developed yet while viral diagnostic methods were already developed and firmly established in a lot of countries as a first step for the preparedness of Ebola outbreak. Some potential therapeutic materials including ZMapp were supplied and the treated people got over the EVD. Several candidates of vaccines also were investigated their efficacy in animal models by National Institute of Health (NIH) and Department of Defense, and they are processing of clinical tests in West Africa aiming to finish the development by the 2015. Vaccine and therapeutic development is essential to stop the EVD outbreak in West Africa, also to protect the world from the risk which can be generated by potential spread of Ebola virus.
